Despite their promise, small-molecule inhibitors have limitations, as they lead to the development of drug resistance through mechanisms that may include their influence on tumor microenvironments and the potential reactivation of both MAPK and PI3K/AKT signaling pathways [220,221]. Here, AKT1 is linked to neoplasm.